Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: July 28, 2021
Reporting Period: Second Quarter of 2021
This filing serves as a notification that the Company issued an Earnings Press Release and supplemental information regarding its financial results for the second quarter of 2021. The filing incorporates by reference the press release, supplemental data, and presentation materials used during the earnings conference call.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced exhibits (Exhibit 99.1 Press Release and Exhibit 99.2 Supplemental Information) which are incorporated by reference but not detailed in the body of this 8-K filing.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It directs investors to the Earnings Press Release (Exhibit 99.1) for the announcement of financial results and the Supplemental Information (Exhibit 99.2) for further details.
Guidance, Outlook, and Management Commentary
- Management Commentary: The Company posted a presentation (Exhibit 99.3) on its website containing financial and operating initiatives discussed during the July 28, 2021, conference call.
- Non-GAAP Measures: The presentation includes references to non-GAAP financial information. Reconciliations to GAAP measures are available in the Supplemental Information (Exhibit 99.2).
- Regulation FD Disclosure: The information in Item 7.01 is provided for disclosure purposes and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act, nor is it incorporated by reference into future filings unless specifically stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2021 revenue, net income, and earnings per share figures.
- Examine Exhibit 99.2 (Supplemental Information) for reconciliations between non-GAAP and GAAP financial measures.
- Consult Exhibit 99.3 (Presentation Materials) for management's discussion on operating initiatives and future outlook.
- Verify the availability of the presentation on the Company's website, as the Company reserves the right to discontinue access at any time.